This is particularly pertinent when BTK expression is considered, because in vivo models have suggested that, proportionally, there is higher expression and potentially bioavailability of BTK in the microglia compared with astrocytes.10 Targeting of microglia alongside B cells could be beneficial as effectors of MS pathogenesis.34 The gene discussed is BTK; the disease is myeloid sarcoma.